Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 89Active not recruiting 68Completed 19Not yet recruiting 17Terminated 7Suspended 4Withdrawn 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Prostatic Neoplasms 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms 3Recurrence 2Multiple Myeloma 2Leukemia, Myeloid, Acute 2Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Thrombocytopenia 1Sinusitis 1Rib Fractures 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Oligodendroglioma 1Non-Muscle Invasive Bladder Neoplasms 1Mycosis Fungoides 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, B-Cell 1Lymphoma 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Biphenotypic, Acute 1Leukemia 1Glioblastoma 1Desmoid Tumors 1Cytopenia 1Communication Disorders 1Colorectal Neoplasms 1

Interventions

fludarabine 1dexamethasone acetate 1dexamethasone 21-phosphate 1daratumumab 1carfilzomib 1auricularum 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Hyaluronoglucosaminidase 1Dexamethasone 1Cyclophosphamide 1Calcium Dobesilate 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Multiple Myeloma × 30 days × Clear all
NCT07082270 2026-05-15

Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma

Roswell Park Cancer Institute

Phase 1 Withdrawn
Plasma cell

Multiple Myeloma

NCT06698744 2026-05-13

UF-KURE-BCMA CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma

Case Comprehensive Cancer Center

Phase 1 Withdrawn
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡